Blood News and Research

RSS

Renowned experts discuss new approaches to cancer therapy at international conference

An international conference attended by more than 70 of the world's leading experts and investigators in the field of Ephs and ephrins was held locally this week and hosted by Waldemar Debinski, M.D., Ph.D., director of the Brain Tumor Center of Excellence at Wake Forest University Baptist Medical Center.

30 Jun 2010

5-month-old, 4 pound infant receives lifesaving liver transplant

A 5-month-old New York infant received a lifesaving liver transplant for advanced liver failure diagnosed following her birth 10 weeks premature. One of the smallest babies ever to successfully receive a liver transplant, she weighed 4 pounds at the time of the surgery.

30 Jun 2010

Repeated viral screening for ART patients unnecessary with each donation

European legislation that requires all couples undergoing assisted reproduction treatment (ART) to be screened for HIV and hepatitis at the time of every sperm or egg donation is unnecessary, expensive, and potentially distressing for patients, the 26th annual meeting of the European Society of Human Reproduction and Embryology heard today (Monday).

30 Jun 2010

InNexus develops IXS312 small protein fragment as topical therapy for AMD, diabetic retinal dysplasia

InNexus Biotechnology Inc., a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced that it has developed IXS312(VEGF), an antibody fragment with activity against the growth factor VEGF for planned use in ocular treatments.

30 Jun 2010

Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients

In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment was compared with standard glucose control.

30 Jun 2010

Study highlights importance of individualized, patient-centered therapies

In an analysis from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, one of the largest studies of its kind to determine whether intensive blood glucose (sugar) control worked better than standard blood sugar control among diabetics, results show that the benefits of intensive therapy need to be balanced against the increase in total and cardiovascular disease-related death, increased weight gain, and high risk for severe low blood sugar.

30 Jun 2010

2 new studies add to evidence of risks with diabetes drug Avandia as FDA prepares to debate it's safety

The Washington Post: Two new studies provide evidence "that the diabetes drug Avandia increases the risk of heart problems and strokes, renewing questions about the safety of the medication. ... The new research, released Monday, should prompt the Food and Drug Administration to remove the drug from the market, according to the researchers who led the analyses and several drug-safety advocates.

30 Jun 2010

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.

30 Jun 2010

AccuVein's AV300 vein illumination device installed in majority of U.S. hospitals

AccuVein announced today that its groundbreaking AV300 vein illumination device has been installed in more than 275 hospitals throughout the United States, less than 12 months after the product began shipping.

30 Jun 2010

Uganda children have high blood lead levels: Researchers

Researchers at Mount Sinai School of Medicine have found that children living near the Kiteezi landfill in Kampala, Uganda, have blood lead levels nearly 20 times as high as the typical lead level found in U.S. children.

30 Jun 2010

Oxygen can combat wrinkle formation by reducing UVB damage

It's no secret that UVB radiation from the sun causes wrinkles. However, a Japanese study published in the American Journal of Physiology—Regulatory, Integrative and Comparative Physiology (http://ajpregu.physiology.org/) indicates that oxygen may help combat the formation of wrinkles by lessening tissue damage done by UVB rays.

30 Jun 2010

Study indicates two treatment strategies can reduce progression of diabetic retinopathy

In high-risk adults with type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.

30 Jun 2010

Importance of cell-cell communication in ischaemia

A team from the Bristol Heart Institute have investigated the importance of cell-cell communication in regulating the formation of new blood vessels following the restriction in blood supply to the heart or back leg in mice.

29 Jun 2010

BBD reports analyze effectiveness and safety of statin use

A series of new reports from Consumer Reports Best Buy Drugs (BBD) caution that the benefits of statin use by children and some women may not outweigh the risks. Drugs to lower cholesterol - including statins - are the most commonly prescribed drugs in the U.S. and garnered more than $14 billion in sales last year.

29 Jun 2010

Successful growth of mouse embryonic stem cells in rat lungs raises hopes for engineering human transplants

For someone with a severe, incurable lung disorder such as cystic fibrosis or chronic obstructive pulmonary disease, a lung transplant may be the only chance for survival. Unfortunately, it's often not a very good chance. Matching donor lungs are rare, and many would-be recipients die waiting for the transplants that could save their lives.

29 Jun 2010

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

Chelsea Therapeutics International, Ltd. announced the initiation of Study 306, a pivotal Phase III trial evaluating the efficacy of NORTHERA™, an oral synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with Parkinson's disease.

29 Jun 2010

Vitae earns $14M milestone payment from Boehringer Ingelheim

Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance with Boehringer Ingelheim. The payment recognizes Boehringer Ingelheim's recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials.

29 Jun 2010

New tool could aid in diagnosing Alzheimer's, track disease progression

A trial of a novel radioactive compound readily and safely distinguished the brains of Alzheimer's disease patients from healthy volunteers on brain scans and opens the doors to making such imaging available beyond facilities that can manufacture their own radioactive compounds.

29 Jun 2010

Rosiglitazone therapy associated with increased risk for heart attack: Study

Eleven years after the introduction of the diabetes drug rosiglitazone, data from available clinical trials demonstrate an increased risk for heart attack associated with its use and suggest an unfavorable benefit-to-risk ratio, according to a report posted online today that will appear in the July 26 print issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

29 Jun 2010

Phytonutrient-based medical food and heart-healthy diet reduce CVD risk factors: Study

New research presented at the American Diabetes Association's 70th Scientific Sessions in Orlando, Florida on June 27, 2010 suggests that a medical food developed by Metagenics, Inc. called UltraMeal® PLUS 360° enhances the cardiovascular disease (CVD) risk-lowering benefits of a Mediterranean-style low-glycemic-load diet.

29 Jun 2010

Blood News and Research

Renowned experts discuss new approaches to cancer therapy at international conference

5-month-old, 4 pound infant receives lifesaving liver transplant

Repeated viral screening for ART patients unnecessary with each donation

InNexus develops IXS312 small protein fragment as topical therapy for AMD, diabetic retinal dysplasia

Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients

Study highlights importance of individualized, patient-centered therapies

2 new studies add to evidence of risks with diabetes drug Avandia as FDA prepares to debate it's safety

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

AccuVein's AV300 vein illumination device installed in majority of U.S. hospitals

Uganda children have high blood lead levels: Researchers

Oxygen can combat wrinkle formation by reducing UVB damage

Study indicates two treatment strategies can reduce progression of diabetic retinopathy

Importance of cell-cell communication in ischaemia

BBD reports analyze effectiveness and safety of statin use

Successful growth of mouse embryonic stem cells in rat lungs raises hopes for engineering human transplants

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

Vitae earns $14M milestone payment from Boehringer Ingelheim

New tool could aid in diagnosing Alzheimer's, track disease progression

Rosiglitazone therapy associated with increased risk for heart attack: Study

Phytonutrient-based medical food and heart-healthy diet reduce CVD risk factors: Study

Changing the landscape of R&D to build clinical success from the ground up

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Latest News